bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on non-invasive diagnostics and early cancer detection, today announced initiation of the Company's planned ...
A procedure that can help spot lung cancer early is now available at a hospital, saving patients long trips out of a county.
InvestorsHub on MSN
BioAffinity launches large-scale clinical study for lung cancer detection technology
Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...
For asymptomatic people without known risks, the downsides and uncertainties of multi-cancer early detection testing could ...
Lung cancer is classified into non-small cell and small cell types, influencing treatment strategies and prognosis. Advances in targeted therapies, immunotherapy, and minimally invasive surgeries have ...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today ...
SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF) announced a study with Brooke Army Medical Center to validate its CyPath Lung diagnostic test using sputum samples collected through tracheal ...
Lung cancer survivor Shira Boehler and Dr. Kim Lori Sandler join 'Fox & Friends Weekend' to discuss Boehler's 'shocking' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results